Company Monitoring Page for Amgen

job ratings (see below graph) for Amgen

latest headlines for company on cafepharma

J&J sues Amgen over plan to sell drug similar to Stelara
Business Insurance
Thu, 12/1/22 - 10:48 am
Tags:
JNJ, Janssen, Amgen, legal, ulcerative colitis, patents, Stelara
Large pharmas probe takeover of Horizon Therapeutics
BioPharma Dive
Wed, 11/30/22 - 10:58 am
Tags:
Horizon Pharma, M&A, JNJ, Sanofi, Amgen
Mirati is once again the subject of Big Pharma takeover talks: report
Fierce Biotech
Sun, 11/27/22 - 07:08 pm
Tags:
Mirati Therapeutics, M&A, Amgen, Lumakras
Best Places to Work in Biopharma 2023 Report Reveals Most Sought-After Employers
BioSpace
Mon, 11/14/22 - 10:59 am
Tags:
biotech, biopharma, employers, corporate culture, Moderna Therapeutics, Genentech, Pfizer, Amgen, AbbVie
Arrowhead Gets $250M in Royalty Deal for Cardio Drug Heading to Phase 3
MedCity News
Wed, 11/9/22 - 11:30 pm
Tags:
Amgen, Arrowhead Pharmaceuticals, olpasiran, heart disease
Early data hint at benefit for Amgen’s obesity drug
BioPharma Dive
Wed, 11/9/22 - 10:32 am
Tags:
Amgen, obesity, Eli Lilly, Novo Nordisk, AMG 133
Amgen to test new way to lower heart risk with large drug trial
BioPharma Dive
Mon, 11/7/22 - 11:00 am
Tags:
Amgen, clinical trials, heart disease, olpasiran
Amgen's Supreme Court bid answered in long-running Repatha patent feud against Sanofi, Regeneron
Fierce Pharma
Mon, 11/7/22 - 10:55 am
Tags:
Amgen, Repatha, patents, Supreme Court, Sanofi, Regeneron
What Pharma Companies Can Expect From the Influx of Humira Biosimilars
Drug Channels
Fri, 10/14/22 - 10:15 am
Tags:
AbbVie, Humira, biosimilars, Amgen, Amjevita
Amgen study: Biosimilars saved the healthcare system $21B
Medical Marketing and Media
Wed, 10/12/22 - 11:38 pm
Tags:
Amgen, biosimilars
Why Amgen Is Up More Than 6% Today
Motley Fool
Tue, 10/11/22 - 04:05 pm
Tags:
Amgen, AMG133, obesity
R&D acceleration: Amgen opens its second largest research site, with lab and office space for 650 staff
Endpoints
Fri, 10/7/22 - 11:02 am
Tags:
Amgen, R&D
SITC 2022 preview – cytokines and oral checkpoints
EP Vantage
Thu, 10/6/22 - 10:39 am
Tags:
SITC, Incyte, ChemoCentryx, Amgen, cytokines
No big bang for biopharma buyouts
EP Vantage
Wed, 10/5/22 - 10:29 am
Tags:
M&A, Pfizer, Global Blood Therapeutics, Amgen, ChemoCentryx, Novo Nordisk, Forma, Alcon, Aerie Pharmaceuticals, Gilead Sciences, MiroBio
Biden admin says Supreme Court should reject Amgen's petition to take up Repatha patent case
Fierce Pharma
Thu, 09/22/22 - 11:14 pm
Tags:
Amgen, patents, Supreme Court, Repatha, Sanofi, Regeneron
Amgen CEO Robert Bradway warns Biden's Inflation Reduction Act could blunt future biotech success stories
Fierce Pharma
Thu, 09/15/22 - 11:22 pm
Tags:
Amgen, Bob Bradway, Pharma CEOs, Inflation Reduction Act
ESMO 2022 movers – KRAS backfires
EP Vantage
Thu, 09/15/22 - 10:12 am
Tags:
ESMO, KRAS inhibitors, Relay Therapeutics, Regeneron, Amgen, Deciphera, Clovis Oncology, Ayala Pharmaceuticals, Springworks, Mirati Therapeutics
ESMO: Amgen's Lumakras confirmatory lung cancer data are here, fanning KRAS battle flames
Fierce Pharma
Sun, 09/11/22 - 11:07 pm
Tags:
Amgen, lung cancer, ESMO, KRAS inhibitors
Could This Biosimilar Drug Candidate Be a Winner for Amgen?
Motley Fool
Fri, 09/9/22 - 10:57 am
Tags:
Amgen, Soliris, biosimilars, ABP 959
Amgen's Neulasta gains another biosimilar competitor as sales slip
Endpoints
Thu, 09/8/22 - 04:35 pm
Tags:
Amgen, Neulasta, Fresenius Kabi, biosimilars, FDA, Stimufend

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.